Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance

Oestrogen receptor (ER) positive breast cancer (BC) patients are eligible for endocrine therapy (ET), regardless of ER immunohistochemical expression level. There is a wide spectrum of ER expression and the response to ET is not uniform. This study aimed to assess the clinical and molecular conseque...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2024-01, Vol.197, p.113473-113473, Article 113473
Main Authors: Makhlouf, Shorouk, Quinn, Cecily, Toss, Michael, Alsaleem, Mansour, Atallah, Nehal M, Ibrahim, Asmaa, Rutland, Catrin S, Mongan, Nigel P, Rakha, Emad A
Format: Article
Language:English
Subjects:
Breast Neoplasms - drug therapy
Female
Humans
Prognosis
Receptors, Estrogen - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c347t-a386c75065bf2a45f6d0a9e8d8b5efb8ead04df844f006c8ad41d433ac2e0bac3
cites cdi_FETCH-LOGICAL-c347t-a386c75065bf2a45f6d0a9e8d8b5efb8ead04df844f006c8ad41d433ac2e0bac3
container_end_page 113473
container_issue
container_start_page 113473
container_title European journal of cancer (1990)
container_volume 197
creator Makhlouf, Shorouk
Quinn, Cecily
Toss, Michael
Alsaleem, Mansour
Atallah, Nehal M
Ibrahim, Asmaa
Rutland, Catrin S
Mongan, Nigel P
Rakha, Emad A
description Oestrogen receptor (ER) positive breast cancer (BC) patients are eligible for endocrine therapy (ET), regardless of ER immunohistochemical expression level. There is a wide spectrum of ER expression and the response to ET is not uniform. This study aimed to assess the clinical and molecular consequences of ER heterogeneity with respect to ET-response. ER expression, categorised by percentage and staining intensity in a large BC cohort (n = 7559) was correlated with clinicopathological parameters and patient ET response. The Cancer Genome Atlas Data BC cohort (n = 1047) was stratified by ER expression and transcriptomic analysis completed to better understand the molecular basis of ER heterogeneity. The quantitative proportional increase in ER expression was positively associated with favourable prognostic parameters. Tumours with 1-9% ER expression were characteristically similar to ER-negative (
doi_str_mv 10.1016/j.ejca.2023.113473
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2903327866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2903327866</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-a386c75065bf2a45f6d0a9e8d8b5efb8ead04df844f006c8ad41d433ac2e0bac3</originalsourceid><addsrcrecordid>eNo9kMFu2zAQRImgRey4_YEcAh5zkbMUKYnqLTDSJkCAoEB7JlbU0qAhky4pBenfV46dnvbyZjD7GLsWsBYg6rvdmnYW1yWUci2EVI28YEuhm7YAXZWf2BLaqi00qHbBrnLeAUCjFVyyhdQCpCybJbM_JwyjH3H0r8Tp7ZAoZx8Dj45HymOKWwo8kaXDGBP3gXeJMI_cYrCUvvHN4IO3OHAMPd_Hgew0YOLZb4N3_p36wj47HDJ9Pd8V-_394dfmsXh--fG0uX8u7Lx9LFDq2jYV1FXnSlSVq3vAlnSvu4pcpwl7UL3TSjmA2mrsleiVlGhLgg6tXLHbU-8hxT_TPN7sfbY0DBgoTtmU7fvTuq5ntDyhNsWcEzlzSH6P6a8RYI5yzc4c5ZqjXHOSO4duzv1Tt6f-f-TDpvwHyOx49A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2903327866</pqid></control><display><type>article</type><title>Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Makhlouf, Shorouk ; Quinn, Cecily ; Toss, Michael ; Alsaleem, Mansour ; Atallah, Nehal M ; Ibrahim, Asmaa ; Rutland, Catrin S ; Mongan, Nigel P ; Rakha, Emad A</creator><creatorcontrib>Makhlouf, Shorouk ; Quinn, Cecily ; Toss, Michael ; Alsaleem, Mansour ; Atallah, Nehal M ; Ibrahim, Asmaa ; Rutland, Catrin S ; Mongan, Nigel P ; Rakha, Emad A</creatorcontrib><description>Oestrogen receptor (ER) positive breast cancer (BC) patients are eligible for endocrine therapy (ET), regardless of ER immunohistochemical expression level. There is a wide spectrum of ER expression and the response to ET is not uniform. This study aimed to assess the clinical and molecular consequences of ER heterogeneity with respect to ET-response. ER expression, categorised by percentage and staining intensity in a large BC cohort (n = 7559) was correlated with clinicopathological parameters and patient ET response. The Cancer Genome Atlas Data BC cohort (n = 1047) was stratified by ER expression and transcriptomic analysis completed to better understand the molecular basis of ER heterogeneity. The quantitative proportional increase in ER expression was positively associated with favourable prognostic parameters. Tumours with 1-9% ER expression were characteristically similar to ER-negative (&lt;1%) tumours. Maximum ET-response was observed in tumours with 100% ER expression, with responses significantly different to tumours exhibiting ER at &lt; 100% and significantly decreased survival rates were observed in tumours with 50% and 10% of ER expression. The Histochemical-score (H-score), which considers both staining intensity and percentage, added significant prognostic value over ER percentage alone with significant outcome differences observed at H-scores of 30, 100 and 200. There was a positive correlation between ER expression and ESR1 mRNA expression and expression of ER-regulated genes. Pathway analysis identified differential expression in key cancer-related pathways in different ER-positive groups. ET-response is statistically proportionally related to ER expression with significant differences observed at 10%, 50% and 100%. The H-score adds prognostic and predictive information.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2023.113473</identifier><identifier>PMID: 38103327</identifier><language>eng</language><publisher>England</publisher><subject>Breast Neoplasms - drug therapy ; Female ; Humans ; Prognosis ; Receptors, Estrogen - metabolism</subject><ispartof>European journal of cancer (1990), 2024-01, Vol.197, p.113473-113473, Article 113473</ispartof><rights>Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-a386c75065bf2a45f6d0a9e8d8b5efb8ead04df844f006c8ad41d433ac2e0bac3</citedby><cites>FETCH-LOGICAL-c347t-a386c75065bf2a45f6d0a9e8d8b5efb8ead04df844f006c8ad41d433ac2e0bac3</cites><orcidid>0000-0003-3889-9659 ; 0000-0002-7689-2493</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38103327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Makhlouf, Shorouk</creatorcontrib><creatorcontrib>Quinn, Cecily</creatorcontrib><creatorcontrib>Toss, Michael</creatorcontrib><creatorcontrib>Alsaleem, Mansour</creatorcontrib><creatorcontrib>Atallah, Nehal M</creatorcontrib><creatorcontrib>Ibrahim, Asmaa</creatorcontrib><creatorcontrib>Rutland, Catrin S</creatorcontrib><creatorcontrib>Mongan, Nigel P</creatorcontrib><creatorcontrib>Rakha, Emad A</creatorcontrib><title>Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Oestrogen receptor (ER) positive breast cancer (BC) patients are eligible for endocrine therapy (ET), regardless of ER immunohistochemical expression level. There is a wide spectrum of ER expression and the response to ET is not uniform. This study aimed to assess the clinical and molecular consequences of ER heterogeneity with respect to ET-response. ER expression, categorised by percentage and staining intensity in a large BC cohort (n = 7559) was correlated with clinicopathological parameters and patient ET response. The Cancer Genome Atlas Data BC cohort (n = 1047) was stratified by ER expression and transcriptomic analysis completed to better understand the molecular basis of ER heterogeneity. The quantitative proportional increase in ER expression was positively associated with favourable prognostic parameters. Tumours with 1-9% ER expression were characteristically similar to ER-negative (&lt;1%) tumours. Maximum ET-response was observed in tumours with 100% ER expression, with responses significantly different to tumours exhibiting ER at &lt; 100% and significantly decreased survival rates were observed in tumours with 50% and 10% of ER expression. The Histochemical-score (H-score), which considers both staining intensity and percentage, added significant prognostic value over ER percentage alone with significant outcome differences observed at H-scores of 30, 100 and 200. There was a positive correlation between ER expression and ESR1 mRNA expression and expression of ER-regulated genes. Pathway analysis identified differential expression in key cancer-related pathways in different ER-positive groups. ET-response is statistically proportionally related to ER expression with significant differences observed at 10%, 50% and 100%. The H-score adds prognostic and predictive information.</description><subject>Breast Neoplasms - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Prognosis</subject><subject>Receptors, Estrogen - metabolism</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kMFu2zAQRImgRey4_YEcAh5zkbMUKYnqLTDSJkCAoEB7JlbU0qAhky4pBenfV46dnvbyZjD7GLsWsBYg6rvdmnYW1yWUci2EVI28YEuhm7YAXZWf2BLaqi00qHbBrnLeAUCjFVyyhdQCpCybJbM_JwyjH3H0r8Tp7ZAoZx8Dj45HymOKWwo8kaXDGBP3gXeJMI_cYrCUvvHN4IO3OHAMPd_Hgew0YOLZb4N3_p36wj47HDJ9Pd8V-_394dfmsXh--fG0uX8u7Lx9LFDq2jYV1FXnSlSVq3vAlnSvu4pcpwl7UL3TSjmA2mrsleiVlGhLgg6tXLHbU-8hxT_TPN7sfbY0DBgoTtmU7fvTuq5ntDyhNsWcEzlzSH6P6a8RYI5yzc4c5ZqjXHOSO4duzv1Tt6f-f-TDpvwHyOx49A</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Makhlouf, Shorouk</creator><creator>Quinn, Cecily</creator><creator>Toss, Michael</creator><creator>Alsaleem, Mansour</creator><creator>Atallah, Nehal M</creator><creator>Ibrahim, Asmaa</creator><creator>Rutland, Catrin S</creator><creator>Mongan, Nigel P</creator><creator>Rakha, Emad A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3889-9659</orcidid><orcidid>https://orcid.org/0000-0002-7689-2493</orcidid></search><sort><creationdate>202401</creationdate><title>Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance</title><author>Makhlouf, Shorouk ; Quinn, Cecily ; Toss, Michael ; Alsaleem, Mansour ; Atallah, Nehal M ; Ibrahim, Asmaa ; Rutland, Catrin S ; Mongan, Nigel P ; Rakha, Emad A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-a386c75065bf2a45f6d0a9e8d8b5efb8ead04df844f006c8ad41d433ac2e0bac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Breast Neoplasms - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Prognosis</topic><topic>Receptors, Estrogen - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Makhlouf, Shorouk</creatorcontrib><creatorcontrib>Quinn, Cecily</creatorcontrib><creatorcontrib>Toss, Michael</creatorcontrib><creatorcontrib>Alsaleem, Mansour</creatorcontrib><creatorcontrib>Atallah, Nehal M</creatorcontrib><creatorcontrib>Ibrahim, Asmaa</creatorcontrib><creatorcontrib>Rutland, Catrin S</creatorcontrib><creatorcontrib>Mongan, Nigel P</creatorcontrib><creatorcontrib>Rakha, Emad A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Makhlouf, Shorouk</au><au>Quinn, Cecily</au><au>Toss, Michael</au><au>Alsaleem, Mansour</au><au>Atallah, Nehal M</au><au>Ibrahim, Asmaa</au><au>Rutland, Catrin S</au><au>Mongan, Nigel P</au><au>Rakha, Emad A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2024-01</date><risdate>2024</risdate><volume>197</volume><spage>113473</spage><epage>113473</epage><pages>113473-113473</pages><artnum>113473</artnum><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Oestrogen receptor (ER) positive breast cancer (BC) patients are eligible for endocrine therapy (ET), regardless of ER immunohistochemical expression level. There is a wide spectrum of ER expression and the response to ET is not uniform. This study aimed to assess the clinical and molecular consequences of ER heterogeneity with respect to ET-response. ER expression, categorised by percentage and staining intensity in a large BC cohort (n = 7559) was correlated with clinicopathological parameters and patient ET response. The Cancer Genome Atlas Data BC cohort (n = 1047) was stratified by ER expression and transcriptomic analysis completed to better understand the molecular basis of ER heterogeneity. The quantitative proportional increase in ER expression was positively associated with favourable prognostic parameters. Tumours with 1-9% ER expression were characteristically similar to ER-negative (&lt;1%) tumours. Maximum ET-response was observed in tumours with 100% ER expression, with responses significantly different to tumours exhibiting ER at &lt; 100% and significantly decreased survival rates were observed in tumours with 50% and 10% of ER expression. The Histochemical-score (H-score), which considers both staining intensity and percentage, added significant prognostic value over ER percentage alone with significant outcome differences observed at H-scores of 30, 100 and 200. There was a positive correlation between ER expression and ESR1 mRNA expression and expression of ER-regulated genes. Pathway analysis identified differential expression in key cancer-related pathways in different ER-positive groups. ET-response is statistically proportionally related to ER expression with significant differences observed at 10%, 50% and 100%. The H-score adds prognostic and predictive information.</abstract><cop>England</cop><pmid>38103327</pmid><doi>10.1016/j.ejca.2023.113473</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-3889-9659</orcidid><orcidid>https://orcid.org/0000-0002-7689-2493</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0959-8049
ispartof European journal of cancer (1990), 2024-01, Vol.197, p.113473-113473, Article 113473
issn 0959-8049
1879-0852
language eng
recordid cdi_proquest_miscellaneous_2903327866
source ScienceDirect Freedom Collection 2022-2024
subjects Breast Neoplasms - drug therapy
Female
Humans
Prognosis
Receptors, Estrogen - metabolism
title Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T23%3A43%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quantitative%20expression%20of%20oestrogen%20receptor%20in%20breast%20cancer:%20Clinical%20and%20molecular%20significance&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Makhlouf,%20Shorouk&rft.date=2024-01&rft.volume=197&rft.spage=113473&rft.epage=113473&rft.pages=113473-113473&rft.artnum=113473&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2023.113473&rft_dat=%3Cproquest_cross%3E2903327866%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c347t-a386c75065bf2a45f6d0a9e8d8b5efb8ead04df844f006c8ad41d433ac2e0bac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2903327866&rft_id=info:pmid/38103327&rfr_iscdi=true